Sarah Gheuens's most recent trade in Agios Pharmaceuticals Inc was a trade of 11,914 Stock options (right to buy) done . Disclosure was reported to the exchange on July 9, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2025 | 11,914 | 32,086 | - | - | Stock options (right to buy) | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.01 per share. | 09 Jul 2025 | 11,914 | 73,185 (0%) | 0% | 25.0 | 297,969 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.93 per share. | 09 Jul 2025 | 11,067 | 62,118 (0%) | 0% | 37.9 | 419,771 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.76 per share. | 09 Jul 2025 | 847 | 61,271 (0%) | 0% | 38.8 | 32,830 | Common stock |
Viridian Therapeutics Inc | Sarah Gheuens | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 21,000 | 21,000 | - | - | Stock Option (Right to Buy) | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2025 | 8,374 | 65,362 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2025 | 8,374 | 8,375 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Gheuens Sarah | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.17 per share. | 01 Jul 2025 | 4,091 | 61,271 (0%) | 0% | 34.2 | 139,789 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 59,897 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 6,000 | - | - | Performance share units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 2,909 | 56,988 (0%) | 0% | 33.5 | 97,568 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 43,500 | 43,500 | - | - | Stock options (right to buy) | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 12,000 | 12,000 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 55,578 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 11,333 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,000 | 4,000 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,000 | 51,098 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,833 | 48,235 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,833 | 0 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 53,897 (0%) | 0% | 35.5 | 59,743 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,187 | 49,911 (0%) | 0% | 35.5 | 42,186 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,137 | 47,098 (0%) | 0% | 35.5 | 40,409 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 8,375 | 47,441 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 8,375 | 16,749 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.85 per share. | 01 Jul 2024 | 3,705 | 43,736 (0%) | 0% | 43.8 | 162,464 | Common stock |
Viridian Therapeutics Inc | Sarah Gheuens | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 21,000 | 21,000 | - | - | Stock Option (Right to Buy) | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 60,000 | 60,000 | - | - | Stock options (right to buy) | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 17,000 | 17,000 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 4,000 | 40,415 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 4,000 | 8,000 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 3,834 | 37,708 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 3,834 | 3,833 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 1,349 | 39,066 (0%) | 0% | 32.6 | 43,937 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 1,293 | 36,415 (0%) | 0% | 32.6 | 42,113 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 2,162 | 0 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 2,162 | 34,073 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Gheuens Sarah | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.14 per share. | 12 Feb 2024 | 642 | 33,431 (0%) | 0% | 25.1 | 16,140 | Common stock |
Agios Pharmaceuticals Inc | Gheuens Sarah | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,750 | 0 | - | - | Performance share units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,750 | 33,619 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.64 per share. | 20 Jan 2024 | 1,708 | 31,911 (0%) | 0% | 21.6 | 36,961 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 5,000 | 29,658 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Gheuens Sarah | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 5,000 | 0 | - | - | Performance share units | |
Agios Pharmaceuticals Inc | Gheuens Sarah | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.99 per share. | 05 Jan 2024 | 1,789 | 27,869 (0%) | 0% | 23.0 | 41,129 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2023 | 25,124 | 25,124 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,750 | 5,750 | - | - | Performance share units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,750 | 25,866 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.36 per share. | 28 Jun 2023 | 1,707 | 24,159 (0%) | 0% | 28.4 | 48,411 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 44,000 | 44,000 | - | - | Stock options (right to buy) | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 12,000 | 12,000 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 3,833 | 21,250 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 3,833 | 7,667 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.02 per share. | 01 Mar 2023 | 1,134 | 20,116 (0%) | 0% | 25.0 | 28,373 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,162 | 2,162 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,162 | 17,767 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.44 per share. | 10 Feb 2023 | 758 | 17,009 (0%) | 0% | 28.4 | 21,558 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2022 | 9,375 | 0 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2022 | 9,375 | 18,388 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.48 per share. | 23 Dec 2022 | 2,783 | 15,605 (0%) | 0% | 28.5 | 79,260 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 833 | 0 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 833 | 9,261 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.83 per share. | 02 Dec 2022 | 248 | 9,013 (0%) | 0% | 28.8 | 7,150 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 41,000 | 41,000 | - | - | Stock options (right to buy) | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,500 | 11,500 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 3,271 | 3,272 | - | - | Performance share units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 3,271 | 8,723 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 18 Feb 2022 | 955 | 7,768 (0%) | 0% | 29.1 | 27,771 | Common stock |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 2,162 | 4,324 | - | - | Restricted stock units | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 2,162 | 6,210 (0%) | 0% | 0 | Common stock | |
Agios Pharmaceuticals Inc | Sarah Gheuens | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. | 10 Feb 2022 | 758 | 5,452 (0%) | 0% | 31.4 | 23,820 | Common stock |